Publication

Time to treatment with bridging intravenous alteplase before endovascular treatment:subanalysis of the randomized controlled SWIFT-DIRECT trial.

Journal Paper/Review - Jul 28, 2022

Units
PubMed
Doi
Contact

Citation
Meinel T, Kaesmacher J, Buetikofer L, Strbian D, Eker O, Cognard C, Mordasini P, Deppeler S, Mendes Pereira V, Albucher J, Darcourt J, Bourcier R, Guillon B, Papagiannaki C, Costentin G, Sibolt G, Räty S, Gory B, Richard S, Liman J, Ernst M, Boulanger M, Barbier C, Mechtouff L, Zhang L, Marnat G, Sibon I, Nikoubashman O, Reich A, Consoli A, Weisenburger-Lile D, Requena M, Garcia-Tornel A, Saleme S, Moulin S, Pagano P, Saliou G, Carrera E, Janot K, Boix M, Pop R, Della Schiava L, Luft A, Piotin M, Gentric J, Pikula A, Pfeilschifter W, Arnold M, Siddiqui A, Froehler M, Furlan A, Chapot R, Wiesmann M, Machi P, Diener H, Kulcsar Z, Bonati L, Bassetti C, Escalard S, Liebeskind D, Saver J, Fischer U, Gralla J, SWIFT-DIRECT investigators. Time to treatment with bridging intravenous alteplase before endovascular treatment:subanalysis of the randomized controlled SWIFT-DIRECT trial. J Neurointerv Surg 2022; 15:e102-e110.
Type
Journal Paper/Review (English)
Journal
J Neurointerv Surg 2022; 15
Publication Date
Jul 28, 2022
Issn Electronic
1759-8486
Pages
e102-e110
Brief description/objective

We hypothesized that treatment delays might be an effect modifier regarding risks and benefits of intravenous thrombolysis (IVT) before mechanical thrombectomy (MT).